IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Pharma/fine chemicals roundup—23 April

6:54 AM MDT | April 23, 2013 | Deepti Ramesh

Hikma to retain injectables business Hikma Pharmaceuticals (London) says it has concluded a review of the strategic options for its global Injectables business and decided that this business should remain part of the Hikma group. Hikma's operations are conducted through three pharmaceutical businesses—branded, injectables, and generics, based mainly in the Mideast and North Africa regions, the United States, and Europe. Hikma recorded sales of about $1.1 billion in 2012. “After a thorough review of strategic options for the injectables business, we...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa